miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?
Journal of Alzheimer's Disease Reports · 2025-12 · 9
DOI: 10.1177/25424823251352166 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Alzheimer's Disease Reports, online erschienen am 25.06.2025. Verfasst von Muhammad Wasim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Maternal and Children's Health Research Institute, Shunde Women and Children's Hospital, Guangdong Medical University, Foshan, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, NSAF Joint Fund.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a neurodegenerative disorder driven by amyloid-β accumulation, tau pathology, and synaptic dysfunction. Recent studies highlight miR-137, a brain-enriched microRNA, as a pivotal regulator of AD pathogenesis. This review synthesizes evidence that miR-137 modulates amyloid-β production, tau phosphorylation, synaptic plasticity, and neuroinflammation, while also preserving mitochondrial function and mitigating oxidative stress. Notably, circulating miR-137 levels correlate with AD progression, offering promise as a non-invasive diagnostic biomarker. Beyond diagnostics, miR-137's ability to target multiple AD-related pathways positions it as a novel therapeutic candidate for neuroprotection. Hence, miR-137 serves as both a biomarker and therapeutic target, offering promising strategies to slow AD progression and improve outcomes. Our bioinformatic analyses further identify miR-137-regulated genes and disrupted networks, underscoring its central role in AD. By bridging molecular mechanisms and clinical potential, miR-137-based strategies could transform AD management, addressing both pathological hallmarks and cognitive decline. Hence, this review article consolidates evidence of miR-137's multifaceted functions in AD, encouraging further investigation into its molecular mechanisms and translational potential to address this pathogenic condition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Maternal and Children's Health Research Institute, Shunde Women and Children's Hospital, Guangdong Medical University, Foshan, China.
- Institute of Pediatric, Shunde Women and Children Hospital, Guangdong Medical University, Foshan, China.
- Department of Pediatrics, Shunde Women and Children Hospital, Guangdong Medical University, Foshan, China.
ORCID-Profile: Muhammad Wasim, Junhao Guo, Zhendong Wang, Rabia Parveen, Yajun Wang, Guoda Ma
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- NSAF Joint Fund
Zitieren
APA
Wasim, M., Guo, J., Wang, Z., Parveen, R., Chen, R., Wang, Y., & Ma, G. (2025). miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?. Journal of Alzheimer's Disease Reports, 9. https://doi.org/10.1177/25424823251352166
Vancouver
Wasim M, Guo J, Wang Z, Parveen R, Chen R, Wang Y, et al. miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?. Journal of Alzheimer's Disease Reports. 2025;9. doi:10.1177/25424823251352166
BibTeX
@article{Wasim2025,
author = {Wasim, Muhammad and Guo, Junhao and Wang, Zhendong and Parveen, Rabia and Chen, Riling and Wang, Yajun and Ma, Guoda},
title = {miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?},
journal = {Journal of Alzheimer's Disease Reports},
year = {2025},
volume = {9},
doi = {10.1177/25424823251352166}
}
EUVIMED